Stellula Therapeutics
Biotechnology Research • 
Charlottesville, Virginia, United States • 1-10 Employees
Company overview
| Headquarters | Charlottesville, Virginia, United States |
| NAICS | 541714 |
| Employees | 1-10 |
Key Contact at Stellula Therapeutics
Caeley Reever
Co-Founder, CSO
About Stellula Therapeutics
Stellula Therapeutics is a biotechnology company developing next-generation gene therapies for rare and devastating neurological disorders. Our lead program, STEL8, uses advanced gene editing technology to target SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE)—a severe pediatric genetic disorder caused by mutations in the Nav1.6 sodium channel. Current treatment options for SCN8A-DEE are limited, symptom-based, and often ineffective. At Stellula, we take a curative approach—correcting the underlying genetic mutations to deliver a permanent fix for life. In preclinical models, STEL8 has demonstrated promising results: improved survival, reduced seizures, and restoration of normal neuronal activity. Co-founded by experts in sodium channel biology and gene editing, Stellula is at the forefront of precision neurotherapeutics. We are driven by a singular mission: to give children with genetic epilepsies a real chance at life.
Stellula Therapeutics revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Stellula Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Stellula Therapeutics has never raised funding before.
South Africa
Sweden
Frequently asked questions
4.8
40,000 users
